CoChat

Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients

Open access
Chen, Li-Chia, Chen, Teng-Chou, Huang, Yaw-Bin, Chang, Chao-Sung · 2014 · International Journal of Clinical Pharmacy

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The launch of imatinib has turned chronic myeloid leukaemia (CML) into a chronic illness due to the dramatic improvement in survival. Several recent studies have demonstrated that poor adherence to imatinib may hamper the therapeutic outcomes and result in increased medical expenditures, whilst research on exploring the reasons for non-adherence to imatinib is still limited. OBJECTIVE: This study aimed to explore the experience of patients as they journey through their CML treatments and associated imatinib utilisation in order to understand the perceptions, attitudes and concerns that may influence adherence to imatinib treatment. SETTING: This study was conducted at oncology outpatient clinics in a medical centre in southern Taiwan. METHODS: CML patients who regularly attended the oncology outpatient clinics to receive imatinib treatment from October 2011 to March 2012 were invited to participate in the study. Semi-structured face-to-face interviews were used to explore patients' experiences and views of their treatment, their current CML status and CML-related health conditions, their concerns about imatinib treatment and imatinib-taking behaviours. Patient interviews were recorded, transcribed verbatim and thematically analysed using the constant comparison approach. MAIN OUTCOME MEASURE: Themes related to patients' views of the disease and health conditions, worries and concerns influencing imatinib utilisation behaviours are reported. RESULTS: Forty-two CML patients participated in the interviews. The emerging themes included: acceptance of current disease and health status, misconceptions about disease progression, factors associated with adherence to imatinib, concerns and management of adverse drug effects. Participants regarded CML as a chronic disease but had misconceptions about disease progression, therapeutic monitoring, resistance to imatinib and symptoms of side effects. Participants were generally adherent to imatinib and favoured long-term prescriptions to avoid regular outpatient visits for medication refills. Experiencing adverse effect was the main reason influencing adherence and led to polypharmacy. Most participants altered medicine-taking behaviours to maintain long-term use of imatinib. CONCLUSION: Taiwanese CML patients are adherent to imatinib but report changing their medication-taking behaviour due to adverse drug effects and associated polypharmacy. Patients' misconceptions of the disease and medication suggests that it is necessary to improve communication between patients and healthcare professionals. Routinely providing updated information as part of the patient counselling process should be considered as a means of improving this communication.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11096-013-9867-8

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 39

Metadata

Authors
Chen, L.-C., Chen, T.-C., Huang, Y.-B., & Chang, C.-S.
Affiliations
  • University of Nottingham (GB)
  • Kaohsiung Medical University (TW)
Corresponding author
Chen, Li-Chia
Venue
International Journal of Clinical Pharmacy
Published
2013-10-24
Volume
36
Issue
1
Pages
120-127
ISSN
  • 2210-7703 (ISSN-L)
  • 2210-7711
OpenAlex
W2032936189
Cited by
39
References
37
Citations by year
2026: 1 · 2024: 2 · 2023: 5 · 2022: 6 · 2021: 2 · 2020: 4 · 2019: 2 · 2018: 2 · 2017: 4 · 2016: 6 · 2015: 2 · 2014: 2 · 2013: 1
FWCI
3.17
Type
journal article
Language
en
Open access
Locations
  • International Journal of Clinical Pharmacy (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Nottingham ePrints (University of Nottingham) (submittedVersion, cc-by)
  • Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
  • Repository@Nottingham (University of Nottingham) (submittedVersion, other-oa)
  • Research Explorer (The University of Manchester) (submittedVersion)
Topics
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
  • Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
Keywords
chronic myeloid leukemia, imatinib, medication adherence, patient perspectives, acceptance of illness, adverse drug reactions, polypharmacy, medication-taking behavior, patient counseling, patient-provider communication, Taiwanese patients
MeSH terms
Imatinib Mesylate, Assessment of Medication Adherence, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Benzamides, Female, Humans, Health Knowledge, Attitudes, Practice, Male, Middle Aged, Outpatients, Piperazines, Pyrimidines, Taiwan, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Drug Monitoring, Medication Adherence, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients. https://app.cochat.ai/papers/10.1007/s11096-013-9867-8
The paper
Chen, L.-C., Chen, T.-C., Huang, Y.-B., & Chang, C.-S. (2014). Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients. International Journal of Clinical Pharmacy. https://doi.org/10.1007/s11096-013-9867-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.